Search results
Results From The WOW.Com Content Network
Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily therapies for lowering intraocular pressure with mechanisms to treat patients ...
Alcon Inc. ( German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people. [2]
Aerie Pharmaceuticals is a spin-out from Duke research by co-founder Dr. David Epstein on retinal diseases, glaucoma and dry eye syndrome Durham pharma company acquired by international eye-care ...
The New York City Economic Development Corporation's Early Stage Life Sciences Funding Initiative and venture capital partners, including Celgene, General Electric Ventures, and Eli Lilly, committed a minimum of US$100 million to help launch 15 to 20 ventures in life sciences and biotechnology in 2014, and in January 2018, the City of New York ...
Shares of Aerie Pharmaceuticals surged 16.3% on Feb. 26 after the ophthalmic pharmaceutical company’s 4Q revenue topped the Street’s estimates. Revenue in the fourth quarter surged 23% ...
Aerie Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering BEDMINSTER, N.J & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Aerie ...
Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. [1] [2] [3] The company is the maker of Botox. [1]
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund ...